Biologics for treating atopic dermatitis

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Lebrikizumab 250 mg solution for injection in pre-filled pen for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.

Funding status

Lebrikizumab 250 mg solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.

Lebrikizumab should be used in line with the additional clinical criteria listed in the Annex.

MAF assistance does not apply to any formulations or strengths of dupilumab or nemolizumab for treating atopic dermatitis.

Biologics for treating atopic dermatitis (Published 5 Oct 2026) [PDF, 195.98 KB] (opens in new tab)

Plain English Summary

Atopic dermatitis, also called eczema, is a long-term (chronic) skin condition that causes inflammation. Common symptoms include red, itchy, dry or flaky skin and small raised bumps. Atopic dermatitis often starts in childhood but can also affect adults. If the skin becomes infected, it may weep or ooze, develop yellow crusty patches, become more swollen or painful, or cause a fever.

Dupilumab, lebrikizumab, and nemolizumab are biologic medicines known as monoclonal antibodies that block certain proteins involved in the inflammation that causes atopic dermatitis. This can help reduce symptoms and improve the skin’s natural barrier. The medicines are given as an injection under the skin (subcutaneously).

Lebrikizumab was recommended for government funding because its benefit justifies its cost. It is included in the Medication Assistance Fund (MAF) (opens in new tab), with its cost subsidised by 40% to 75% for eligible patients. Dupilumab and nemolizumab were not recommended for subsidy.